Salarius Pharmaceuticals is a clinical-stage biotechnology company that focuses on epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat, which is in Phase I/II clinical trials for the treatment of advanced solid tumors and Ewing sarcoma. Salarius Pharmaceuticals has collaborations with various organizations to develop its products and is headquartered in Houston, Texas.